Post-MI Treatment with G-CSF and EPO-liposome with SLX Repairs Infarcted Myocardium Through EPCs Mobilization and Activation of Prosurvival Signals in Rabbits
Overview
Authors
Affiliations
We investigated whether combination therapy of G-CSF and erythropoietin (EPO)-liposome with Siaryl Lewis X (SLX) is more cardioprotective than G-CSF or EPO-liposome with SLX alone. For the purpose of generating myocardial infarction (MI), rabbits underwent 30 minutes of coronary occlusion and 14 days of reperfusion. We administered saline (control group, i.v.,), G-CSF (G group, 10 μg/kg/day × 5 days, i.c., starting at 24 hours after reperfusion), EPO-liposome with SLX (LE group, i.v., 2500 IU/kg EPO containing liposome with SLX, immediately after reperfusion), and G-CSF + EPO-liposome with SLX (LE + G group) to the rabbits. The MI size was the smallest in the LE+G group (14.7 ± 0.8%), and smaller in the G group (22.4 ± 1.5%) and LE group (18.5 ± 1.1%) than in the control group (27.8 ± 1.5%). Compared with the control group, the cardiac function and remodeling of the G, LE, and LE + G groups were improved, and LE + G group tended to show the best improvement. The number of CD31-positive microvessels was the greatest in the LE + G group, greater in the G and LE groups than in the control group. Higher expressions of phosphorylated (p)-Akt and p-ERK were observed in the ischemic area of the LE and LE + G groups. The number of CD34/CXCR4 cells was significantly higher in the G and LE + G groups. The cardiac SDF-1 was more expressed in the G and LE + G groups. In conclusion, Post-MI combination therapy with G-CSF and EPO-liposome with SLX is more cardioprotective than G-CSF or EPO-liposome with SLX alone through EPCs mobilization, neovascularization, and activation of prosurvival signals.
Chen P, Gao Z, Guo M, Pan D, Zhang H, Du J Front Pharmacol. 2024; 15:1353662.
PMID: 38576488 PMC: 10991745. DOI: 10.3389/fphar.2024.1353662.
Morsink M, Severino P, Luna-Ceron E, Hussain M, Sobahi N, Shin S Acta Biomater. 2021; 139:141-156.
PMID: 34818579 PMC: 11041526. DOI: 10.1016/j.actbio.2021.11.022.
Nanoparticle delivery of cardioprotective therapies.
Mendez-Fernandez A, Cabrera-Fuentes H, Velmurugan B, Irei J, Boisvert W, Lu S Cond Med. 2021; 3(1):18-30.
PMID: 34268485 PMC: 8279025.
Lin X, Wang H, Li X Diab Vasc Dis Res. 2021; 18(2):14791641211002473.
PMID: 33779350 PMC: 8481732. DOI: 10.1177/14791641211002473.
Yamada Y, Minatoguchi S, Endo N, Kanamori H, Kawasaki M, Nishigaki K Pharmacol Res Perspect. 2019; 7(1):e00451.
PMID: 30598826 PMC: 6302719. DOI: 10.1002/prp2.451.